Elanco (ELAN)
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$24.50+0.33%
Close 2026-09-04 · 1-day change
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · ELAN
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-09-06. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $24 the market pays 23× p/e — above the 16× p/e peer median but in line with its own 24× history. That premium reflects a durable franchise our peer-anchored $21 fair value understates; treat the 'expensive vs peers' read with medium confidence. Analysts target $23–$30. Note: our $21 fair value sits below the entire analyst range ($23–$30). Even valued only for durable growth at sustainable margins, it's worth about $28 — above today's price, so the premium reflects that growth case, not pure multiple expansion. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $26.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $5.11 | — | — | Analyst | high |
| dcf fcff | 12M | $32.33 | — | — | Analyst | high |
| graham number | 12M | $17.62 | — | — | TTM | high |
| Peer P/FCF | 12M |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$23.00 – $30.00 (median $26.00) · 3 analysts · as of 2026-08-06
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks more expensive than peers.
Around its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| $10.59 |
| 14.1 |
| 0.75 |
| TTM |
| high |
| Peer P/E | 12M | $13.45 | 10.9 | 1.23 | ntm analyst | high |
| Peer P/S | 12M | $28.83 | 2.9 | 9.92 | TTM | high |
| PEG | 12M | $16.03 | 15.1 | 1.06 | TTM | high |
| residual income | 12M | $12.85 | — | — | TTM | high |
| Own P/E history | 12M | $25.59 | 24.1 | 1.06 | TTM | high |
| triangulated | 12M | $19.02 | 16.1 | 1.18 | Triangulated | high |
| Peer P/E | 3Y | $14.04 | 10.9 | 1.29 | Analyst | medium |
| Peer P/S | 3Y | $31.19 | 2.9 | 10.73 | guidance | medium |
| PEG | 3Y | $19.47 | 15.1 | 1.29 | Analyst | medium |
| Own P/E history | 3Y | $31.08 | 24.1 | 1.29 | Analyst | medium |
| Peer P/E | 5Y | $14.14 | 10.9 | 1.30 | Analyst | high |
| Peer P/S | 5Y | $31.41 | 2.9 | 10.81 | guidance | high |
| PEG | 5Y | $19.60 | 15.1 | 1.30 | Analyst | high |
| Own P/E history | 5Y | $31.29 | 24.1 | 1.30 | Analyst | high |